Oxford BioDynamics (LON:OBD) Stock Price Down 7.5% – Time to Sell?

Oxford BioDynamics Plc (LON:OBD) traded down 7.5% during trading on Tuesday . The stock traded as low as GBX 0.26 and last traded at GBX 0.26. 8,408,798 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 34,863,383 shares. The stock had previously closed at GBX 0.28.

Analysts Set New Price Targets

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Oxford BioDynamics in a research report on Wednesday, October 8th.

Oxford BioDynamics Price Performance

The stock has a 50 day moving average of GBX 0.26 and a two-hundred day moving average of GBX 0.38. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The firm has a market capitalization of £11.11 million, a P/E ratio of -0.32 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last announced its quarterly earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.